Solana

Solana EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of Solana (HSDT) as of Oct 20, 2026 is -13.24 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was -392.52 % — a change of -96.63% (higher).

EBIT/Assets

-13.24 %

YoY

-96.63%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of Solana is 2025 -13.24 % . Operating Income to Assets Ratio (EBIT/Assets) of Solana was 2024 -392.52 % . It decreases by -96.63% higher compared to the previous year.

The Solana EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2018
-95.86 USD
Jan 1, 2019
-231.91 USD
Jan 1, 2020
-215.00 USD
Jan 1, 2021
-128.65 USD
Jan 1, 2022
-89.76 USD
Jan 1, 2023
-161.57 USD
Jan 1, 2024
-392.52 USD
Jan 1, 2025
-13.24 USD
The Solana EBIT/Assets history
YEAREBIT/AssetsYoY
-13.24 %-96.63%
-392.52 %+142.94%
-161.57 %+80.01%
-89.76 %-30.23%
-128.65 %-40.16%
-215.00 %-7.29%
-231.91 %+141.93%
-95.86 %-76.71%
-411.57 %+78.49%
-230.59 %+0.00%
-230.59 %-71.40%
-806.39 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Solana Stock analysis

What does Solana do? Helius Medical Technologies develops and markets the PoNS device, a portable neuromodulation stimulator for neurological wellness. The company focuses on non-invasive platform technologies that enhance the brain's healing ability. The PoNS device is authorized as a class II medical device in Canada for short-term treatment of chronic balance deficits caused by mild-to-moderate traumatic brain injury, used alongside physical therapy. It delivers non-invasive neurostimulation to the tongue to induce neuromodulation. Helius Medical Technologies targets healthcare providers and rehabilitation centers that treat patients with traumatic brain injury. The company's product is designed for use in clinical settings under professional guidance, specifically for patients requiring short-term balance deficit therapy. The PoNS device is positioned as a complementary treatment within physical therapy protocols for neurological rehabilitation. The firm's revenue model is based on the sale of the PoNS device to healthcare institutions and rehabilitation facilities. These institutions purchase the device for use in their treatment programs, leveraging its non-invasive neurostimulation technology to address balance deficits in patients with mild-to-moderate traumatic brain injury. The company's focus on neurological wellness through non-invasive solutions drives its commercial strategy. Solana is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Solana stock

Operating Income to Assets Ratio (EBIT/Assets) of Solana is -13.24 % in 2025.

Operating Income to Assets Ratio (EBIT/Assets) of Solana changed from -392.52 % to -13.24 %, representing a -96.63% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) Solana since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s Solana with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Solana

All Key Metrics — Solana